UGMLC investigates lung diseases
Several lung diseases are rated among the "top ten" of mortality causes worldwide. A better understanding of what causes the disease and the development of new therapeutic concepts thus assumes a high relevance for health policy.
Molecular signaling pathways underlying inflammatory and hyperproliferative diseases of the lung and airways are at the focus of the "Universities of Giessen and Marburg Lung Center " (UGMLC). These pathways are linked in multiple ways to the signaling patterns of lung tissue and organ development and serve as a basis for the development of innovative therapeutic concepts. Our goal is an improved, molecularly based, customized and individualized diagnosis and therapy of the respective lung and/or airway disease.
The results of our research will help patients with acute diseases like pneumonia and pneumogenic sepsis, patients with lung cancer, as well as patients with chronic diseases like asthma, chronic obstructive pulmonary disease (COPD), lung fibrosis, and pulmonary hypertension.
The university medical school sites at Giessen and Marburg and the Max-Planck Institute for Heart and Lung Research unite their scientific and clinical competence to make the UGMLC an internationally leading center for research and treatment of pulmonary diseases. The scientific competence and infrastructure at UGMLC will be fortified by the appointment of additional professors, junior researchers, and establishment of the UGMLC Graduate School.